🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Radiolabelled Diclofenac Tablet A

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule completed

    1 trial

  2. Radiolabelled T4 Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule completed

    1 trial

  3. Ramipril tablet 10 mg

    LIGAND PHARMACEUTICALS INC

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  4. Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg

    LIGAND PHARMACEUTICALS INC

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  5. Randomised, bioequivalence clinical trial of atorvastatin 80 mg capsules vs atorvastatin 80 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.

    Laboratorios Tillomed Spain S.L.U

    Hypercholesterolaemia, Prevention of cardiovascular disease

    phase 1 other active

    1 trial

  6. Randomised, bioequivalence clinical trial of rasagiline 1 mg capsules vs rasagiline 1 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.

    Laboratorios Tillomed Spain S.L.U

    Parkinson´s disease

    phase 1 other active

    1 trial

  7. Randomised, crossover bioequivalence clinical trial of donepezil 5 mg capsules vs donepezil 5 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions

    Laboratorios Tillomed Spain S.L.U

    Alzheimer's disease

    phase 1 other active

    1 trial

  8. Randomised, crossover bioequivalence clinical trial of edoxaban 60 mg tablets versus edoxaban 60 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Healthy volunteers

    phase 1 other active

    1 trial

  9. Randomised, crossover bioequivalence clinical trial of escitalopram 10 mg capsules versus escitalopram 10 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Antidepressants

    phase 1 other active

    1 trial

  10. Randomised, crossover bioequivalence clinical trial of linagliptin/metformin 2.5 mg/1000 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fed conditions.

    Laboratorios Tillomed Spain S.L.U

    diabetes

    phase 1 other active

    1 trial

  11. Randomised, crossover bioequivalence clinical trial of memantine 20 mg capsules versus memantine 20 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Alzheimer’s disease

    phase 1 other active

    1 trial

  12. Randomised, crossover bioequivalence clinical trial of vortioxetine 20 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.

    Laboratorios Tillomed Spain S.L.U

    Antidepressant

    phase 1 other active

    1 trial

  13. Randomised, relative bioavailability clinical trial of amylmetacresol, dichlorobenzyl alcohol, lidocaine and vitamin c lozenges after a single oral dose administration to healthy volunteers under fasting conditions in a crossover design.

    Lacuna Pharma Pty Ltd

    healthy volunteer

    phase 1 other active

    1 trial

  14. Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.

    Bioprojet Pharma

    Eosinophilic esophagitis

    phase 1 other active

    1 trial

  15. Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.

    Lacuna Pharma Pty Ltd

    Comparative bioavailability study under fasting conditions

    phase 1 other active

    1 trial

  16. Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is bioavailability)

    phase 1 other active

    1 trial

  17. Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsalicylic acid, tablet, 2.5 mg/50 mg (given as two tablets) to reference product Xarelto 2.5 mg film-coated tablets (given as two tablets) and Aspirin® N 100 mg tablet in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence in healthy subjects)

    phase 1 other active

    1 trial

  18. Randomized, open-label, single-dose, two-period, cross-over, bioequivalence study comparing Linagliptin 5 mg film-coated tablets (Vipharm S.A.) to Trajenta® 5 mg film-coated tablets (Boehringer Ingelheim) in healthy volunteers under fasting conditions.

    Alphapharm Pty Ltd

    Bioequivalence study in healthy volunteers under fasting conditions

    phase 1 other active

    1 trial

  19. Rehabilitation

    United Therapeutics Europe Ltd

    Stroke

    phase 1 other completed

    1 trial

  20. Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous administration in the arm or in the thigh compared to in the abdomen using a ServoPen in healthy subjects.

    Recordati Ireland

    Post-bariatric hypoglycaemia

    phase 1 other active

    1 trial

  21. Repetitive Transcranial Magnetic Stimulation

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 1 other terminated

    1 trial

  22. Replens and coconut oil

    Summit Therapeutics

    Genitourinary Abnormality

    phase 1 other terminated

    1 trial

  23. Reslizumab IV

    Teva Pharma GmbH

    Absolute Bioavailability

    phase 1 small molecule completed

    1 trial

  24. Retifanlimab

    ACTUATE THERAPEUTICS, INC.

    Pancreatic Adenocarcinoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources